| Description |
(S)-PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. (S)-PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research[1].
|
| Related Catalog |
|
| In Vitro |
(S)-PM-43I (0.05-5 µM; 2 h) inhibits IL-4 stimulated phosphorylation of STAT6 in Beas-2B immortalized human airway cells[1]. Western Blot Analysis[1] Cell Line: Beas-2B immortalized human airway cells Concentration: 0.05, 0.1, 0.5, 1, 2.5, 5 µM Incubation Time: 2 h Result: Inhibited STAT6 phosphorylation level to 18%, 21% at 2.5 and 5 µM, respectively.
|
| In Vivo |
(S)-PM-43I (intranasal administration; 5 μg per mouse; every other day; 18 d) activity is restricted to the lung by intranasal administration[1]. Animal Model: Mice injected with Ovalhumin/Alum[1] Dosage: 5 μg per mouse Administration: Intranasal administration; 5 μg per mouse; every other day; 18 days Result: Showed no effect on the sensisization of peripheral spleenocytes to ovalbumin.
|
| References |
[1]. John S. Mcmurray, et al. Stat6 inhibitors. WO2014182928A2.
|
